Merit Medical Systems, Inc. (NASDAQ:MMSI – Free Report) – Zacks Research boosted their FY2026 earnings per share estimates for Merit Medical Systems in a research note issued on Thursday, August 20th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings of $3.73 per share for the year, up from their prior forecast of $3.57. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.81 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q4 2026 earnings at $0.98 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.01 EPS, FY2027 earnings at $4.01 EPS, Q1 2028 earnings at $0.95 EPS, Q2 2028 earnings at $1.11 EPS and FY2028 earnings at $4.32 EPS.
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The firm had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. During the same quarter in the prior year, the firm earned $1.01 earnings per share. Merit Medical Systems’s revenue for the quarter was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS.
Check Out Our Latest Stock Report on MMSI
Merit Medical Systems Stock Performance
MMSI opened at $90.28 on Tuesday. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. Merit Medical Systems has a 12-month low of $59.74 and a 12-month high of $94.75. The firm has a 50 day moving average of $77.88 and a two-hundred day moving average of $72.58. The firm has a market capitalization of $5.39 billion, a PE ratio of 37.31, a P/E/G ratio of 2.28 and a beta of 0.48.
Institutional Trading of Merit Medical Systems
Hedge funds have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC purchased a new position in Merit Medical Systems in the fourth quarter valued at $25,000. Kilter Group LLC acquired a new position in shares of Merit Medical Systems in the second quarter worth about $25,000. Torren Management LLC purchased a new stake in shares of Merit Medical Systems during the 4th quarter worth about $38,000. Covestor Ltd boosted its stake in shares of Merit Medical Systems by 252.6% during the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 336 shares in the last quarter. Finally, Danske Bank A S acquired a new stake in shares of Merit Medical Systems during the 3rd quarter valued at about $42,000. 99.66% of the stock is owned by hedge funds and other institutional investors.
Key Stories Impacting Merit Medical Systems
Here are the key news stories impacting Merit Medical Systems this week:
- Positive Sentiment: Zacks Research raised multiple earnings forecasts. Estimates increased for fiscal 2026 EPS to $3.73 from $3.57, fiscal 2027 EPS to $4.01 from $3.82, and fiscal 2028 EPS to $4.32 from $4.12. Quarterly estimates were also increased for Q2 2027, Q3 2027, Q1 2028 and Q2 2028, signaling expectations for improving profitability over the next several years.
- Positive Sentiment: The upgrades reinforce the company’s recent operating momentum. Merit’s latest reported quarter included revenue growth of 9.5% year over year and EPS of $1.19, well above the $0.96 analyst consensus, while management raised its fiscal 2026 EPS guidance to $4.25-$4.35.
- Positive Sentiment: Growth is being supported by product launches, acquisitions and a broader mix of therapeutic medical products. Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
- Neutral Sentiment: Not all revisions were positive: Zacks trimmed its Q4 2026 EPS forecast slightly to $0.98 from $0.99. Its fiscal 2026 estimate of $3.73 also remains below the broader consensus forecast of $3.81.
- Negative Sentiment: Valuation and execution risks could limit further gains. Merit trades at roughly 37 times earnings, and analysts have flagged tariff exposure and the need to successfully execute its product and acquisition strategy after a 22.2% monthly rally. Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?
Merit Medical Systems Company Profile
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
Featured Articles
- Five stocks we like better than Merit Medical Systems
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
